| Literature DB >> 26561979 |
Jason E Imbriglio1, Dong-Ming Shen1, Rui Liang1, Ken Marby1, Ming You1, Hye Won Youm1, Zhe Feng1, Clare London1, Yusheng Xiong1, Jim Tata1, Andreas Verras1, Margarita Garcia-Calvo1, Xuelei Song1, George H Addona1, Dave G McLaren1, Timothy He1, Beth Murphy1, Dan E Metzger1, Gino Salituro1, Diana Deckman1, Qing Chen1, Xiaoling Jin1, Steven J Stout1, Sheng-Ping Wang1, Larissa Wilsie1, Oksana Palyha1, Seongah Han1, Brian K Hubbard1, Stephen F Previs1, Shirly Pinto1, Andrew Taggart1.
Abstract
DGAT2 plays a critical role in hepatic triglyceride production, and data suggests that inhibition of DGAT2 could prove to be beneficial in treating a number of disease states. This article documents the discovery and optimization of a selective small molecule inhibitor of DGAT2 as well as pharmacological proof of biology in a mouse model of triglyceride production.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26561979 DOI： 10.1021/acs.jmedchem.5b01345
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446